{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T14:41:16Z","timestamp":1711636876265},"reference-count":129,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T00:00:00Z","timestamp":1240531200000},"content-version":"vor","delay-in-days":7845,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[1987,11]]},"DOI":"10.1111\/j.1600-0609.1987.tb01445.x","type":"journal-article","created":{"date-parts":[[2010,7,18]],"date-time":"2010-07-18T13:12:19Z","timestamp":1279458739000},"page":"385-398","source":"Crossref","is-referenced-by-count":4,"title":["The management of myelomatosis"],"prefix":"10.1111","volume":"39","author":[{"given":"D. A. G.","family":"Galton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Brito\u2010Babapulle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,4,24]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1938.tb17113.x"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/25.8.849"},{"key":"e_1_2_1_4_2","first-page":"48","article-title":"Myelomatosis, a case with an unusual course","volume":"65","author":"Bjorn\u2010Hansen R.","year":"1961","journal-title":"Nordiske Med"},{"key":"e_1_2_1_5_2","first-page":"227","article-title":"Megaloblastic anaemia and myxoedema in a patient suffering from myeloma, observed for a period of 16 years","volume":"14","author":"Bichel J.","year":"1964","journal-title":"Folia Clin Int (Barc)"},{"key":"e_1_2_1_6_2","first-page":"741","article-title":"Multiple myeloma. General aspects of diagnosis, course, and survival","volume":"188","author":"Study Committee of the Midwest Cooperative Chemotherapy Group","year":"1964","journal-title":"J Am Med Assoc"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-00377-5.50006-6"},{"key":"e_1_2_1_8_2","first-page":"387","article-title":"Increasing trends of multiple myeloma mortality in England and Wales 1950\u20131979: Are the changes real","volume":"69","author":"Velez R","year":"1982","journal-title":"J Natl Cancer Inst"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910320104"},{"key":"e_1_2_1_10_2","first-page":"46","volume-title":"Multiple myeloma and other paraproteinaemias","author":"Cuzick J.","year":"1986"},{"key":"e_1_2_1_11_2","first-page":"398","article-title":"Abnormal proteins in myeloma","author":"Waldenstr\u00f6m J.","year":"1952","journal-title":"Adv Int Med"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1148\/71.2.157"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.5387.859"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-196311000-00001"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1966.tb05453.x"},{"issue":"462","key":"e_1_2_1_16_2","article-title":"Discrete gammaglobulin (M\u2013) components in serum. Clinical study of 150 subjects without myelomatosis","author":"Hallen J.","year":"1966","journal-title":"Acta Med Scand"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198006123022405"},{"key":"e_1_2_1_18_2","first-page":"50","volume-title":"Clinics in Haematology, Vol 11, Myeloma and related disorders","author":"Kyle RA.","year":"1982"},{"key":"e_1_2_1_19_2","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1182\/blood.V62.1.166.166","article-title":"Clinical, morphological, and cell kinetic differences among multiple myeloma, monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"62","author":"Greipp PR","year":"1983","journal-title":"Blood"},{"key":"e_1_2_1_20_2","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1001\/jama.1984.03340380031018","article-title":"\u2018Benign\u2019 monoclonal gammopathy: a misnomer","volume":"251","author":"Kyle RA.","year":"1984","journal-title":"J Am Med Assoc"},{"key":"e_1_2_1_21_2","first-page":"653","volume-title":"Neoplstic diseases of the blood","author":"Kyle RA","year":"1985"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(47)90375-9"},{"key":"e_1_2_1_23_2","volume-title":"Multiple myeloma","author":"Snapper I","year":"1953"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/157500a0"},{"key":"e_1_2_1_25_2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1182\/blood.V4.3.201.201","article-title":"Urethane (ethyl carbamate) therapy in multiple myeloma","volume":"4","author":"Loge JP","year":"1949","journal-title":"Blood"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(1950)3:2<253::AID-CNCR2820030207>3.0.CO;2-4"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI102362"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1951.03670260026008"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-195303000-00007"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V27.3.328.328"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.1928.01140040002001"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1947.02880030001001"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(49)90013-3"},{"key":"e_1_2_1_34_2","first-page":"1259","article-title":"Duration of survival in multiple myeloma","volume":"24","author":"Feinleib M","year":"1960","journal-title":"J Nat Cancer Inst"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1039\/jr9540002409"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1958.tb42675.x"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(55)92736-7"},{"key":"e_1_2_1_38_2","first-page":"87","article-title":"Evaluation of a new chemotherapeutic agent in the treatment of multiple myeloma. IV. L\u2010phenylalanine mustard (NSC 8806)","volume":"21","author":"Bergsagel DE","year":"1962","journal-title":"Cancer Chemotherapy Rep"},{"key":"e_1_2_1_39_2","first-page":"25","article-title":"Evaluation of melphalan (NSC\u20108806) in treatment of multiple myeloma","volume":"36","author":"Brook J","year":"1964","journal-title":"Cancer Chemother Rep"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.5399.1664"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.149.3683.564"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.3109\/02841866609133129"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V30.1.74.74"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.209.2.251"},{"key":"e_1_2_1_45_2","first-page":"149","article-title":"The treatment of multiple myeloma","volume":"10","author":"Farhangi M","year":"1973","journal-title":"Semin Hematol"},{"key":"e_1_2_1_46_2","first-page":"115","article-title":"Cyclophosphamide in treatment of multiple myeloma","volume":"29","author":"Rivers SL","year":"1964","journal-title":"Cancer Chemother Rep"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1964.03070100052010"},{"key":"e_1_2_1_48_2","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1001\/jama.1969.03150200094011","article-title":"Cyclophosphamide versus melphalan in the treatment of plasma cell myeloma","volume":"207","author":"Rivers SL","year":"1969","journal-title":"J Am Med Assoc"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.5750.640"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1973.tb05733.x"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1980.330"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1980.329"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1980.328"},{"key":"e_1_2_1_54_2","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood.V55.6.1011.1011","article-title":"A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients","volume":"55","author":"Merlini G","year":"1980","journal-title":"Blood"},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1985.tb00792.x"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1952.tb14251.x"},{"key":"e_1_2_1_58_2","first-page":"257","article-title":"A comparison of the effect of prednisone and a placebo in the treatment of multiple myeloma","volume":"16","author":"Mass RE.","year":"1962","journal-title":"Cancer Chemother Rep"},{"key":"e_1_2_1_59_2","first-page":"179","article-title":"Intermittent high dose prednisone (NSC\u201010023) therapy for multiple myeloma","volume":"51","author":"Salmon SE","year":"1967","journal-title":"Cancer Chemother Rep"},{"key":"e_1_2_1_60_2","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1001\/jama.1969.03160090040009","article-title":"Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens","volume":"208","author":"Alexanian R","year":"1969","journal-title":"J Am Med Assoc"},{"key":"e_1_2_1_61_2","first-page":"381","article-title":"Treatment of multiple myeloma in remission with anticancer drugs having cell cycle specific characteristics","volume":"61","author":"Alberts DS","year":"1977","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1985.171"},{"key":"e_1_2_1_63_2","first-page":"345","article-title":"Adriamycin (NSC\u2010123127) in the treatment of alkylator\u2010resistant multiple myeloma","volume":"59","author":"Alberts DS","year":"1975","journal-title":"Cancer Chemother Rep"},{"key":"e_1_2_1_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(76)92710-0"},{"key":"e_1_2_1_65_2","first-page":"789","article-title":"Nitrosoureas in multiple myeloma","volume":"60","author":"Salmon SE.","year":"1976","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_66_2","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1200\/JCO.1983.1.8.510","article-title":"Progress in the treatment of plasma cell myeloma","volume":"1","author":"Bergsagel D.","year":"1983","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_67_2","first-page":"1267","article-title":"Vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group Study","volume":"66","author":"Bonnett J","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_68_2","first-page":"1273","article-title":"Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma","volume":"66","author":"Abramson N","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_69_2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/archinte.1975.00330010149019","article-title":"Remission maintenance therapy for multiple myeloma","volume":"135","author":"Alexanian R","year":"1975","journal-title":"Arch Int Med"},{"key":"e_1_2_1_70_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197712)40:6<2765::AID-CNCR2820400602>3.0.CO;2-X"},{"key":"e_1_2_1_71_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197409)34:3<526::AID-CNCR2820340308>3.0.CO;2-R"},{"key":"e_1_2_1_72_2","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood.V51.6.1005.1005","article-title":"Unmaintained remissions in multiple myeloma","volume":"51","author":"Alexanian R","year":"1978","journal-title":"Blood"},{"key":"e_1_2_1_73_2","first-page":"2911","article-title":"Perturbation of DNA synthesis in multiple myeloma cells following cell\u2010cycle\u2010nonspecific chemotherapy","volume":"34","author":"Alberts DS","year":"1974","journal-title":"Cancer Res"},{"key":"e_1_2_1_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)92941-4"},{"key":"e_1_2_1_75_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.288.6428.1411"},{"key":"e_1_2_1_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(75)91631-1"},{"key":"e_1_2_1_77_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.6063.755"},{"key":"e_1_2_1_78_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1983.tb02074.x"},{"key":"e_1_2_1_79_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1959.00270020001001"},{"key":"e_1_2_1_80_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-41-6-1152"},{"key":"e_1_2_1_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(72)90010-1"},{"key":"e_1_2_1_82_2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1001\/archinte.1975.00330010179023","article-title":"Managing the complications of plasma cell myeloma","volume":"135","author":"Cohen HJ","year":"1975","journal-title":"Arch Int Med"},{"key":"e_1_2_1_83_2","first-page":"865","volume-title":"Growth kinetics and biochemical regulation of normal and malignant cells","author":"Salmon SE","year":"1977"},{"key":"e_1_2_1_84_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.8.1227"},{"key":"e_1_2_1_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(83)90739-0"},{"key":"e_1_2_1_86_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1987.00045.x-i1"},{"key":"e_1_2_1_87_2","doi-asserted-by":"publisher","DOI":"10.1159\/000206984"},{"key":"e_1_2_1_88_2","first-page":"161","article-title":"Allogeneic bone marrow transplantation and idiotype monitoring in multiple myeloma","volume":"25","author":"Ozer H","year":"1984","journal-title":"AACR Abstracts"},{"issue":"17","key":"e_1_2_1_89_2","first-page":"17","article-title":"Bone marrow transplantation in multiple myeloma","volume":"13","author":"Tura S","year":"1985","journal-title":"Exp Haematol"},{"key":"e_1_2_1_90_2","first-page":"1269","article-title":"Identical twin (syngeneic) marrow transplantation for haematologic cancers","volume":"76","author":"Fefer A","year":"1986","journal-title":"J Natl Cancer Inst"},{"key":"e_1_2_1_91_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1986.tb03350.x"},{"key":"e_1_2_1_92_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1986.tb00824.x"},{"key":"e_1_2_1_93_2","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1182\/blood.V69.4.1262.1262","article-title":"Bone marrow transplantation in multiple myeloma. Report from the European Cooperative Group for Bone Marrow Transplantation","volume":"69","author":"Gahrton G","year":"1987","journal-title":"Blood"},{"key":"e_1_2_1_94_2","first-page":"851","article-title":"Plasma cell myeloma: response of melphalan\u2010resistant patients to high\u2010dose intermittent cyclophosphamide","volume":"107","author":"Bergsagel DE","year":"1972","journal-title":"Canad Med Ass J"},{"key":"e_1_2_1_95_2","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood.V62.3.572.572","article-title":"Prednisone pulse therapy for refractory myeloma","volume":"62","author":"Alexanian R","year":"1983","journal-title":"Blood"},{"key":"e_1_2_1_96_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198405243102104"},{"key":"e_1_2_1_97_2","first-page":"1413","article-title":"Treatment of advanced plasma cell myeloma with weekly cyclophosphamide and alternate\u2010day prednisone","volume":"66","author":"Brandes LJ","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_98_2","doi-asserted-by":"crossref","DOI":"10.1111\/j.1600-0609.1987.tb00784.x","article-title":"Weekly low dose cyclophosphamide and laternate\u2010day prednisone: An effective low toxicity regimen for advanced myeloma","author":"Brandes LJ","year":"1987","journal-title":"Eur J Haematol"},{"key":"e_1_2_1_99_2","unstructured":"WilsonK ShelleyW BelchA et al.An evaluation of two schedules of cyclophosphamide and prednisone as secondary therapy in multiple myeloma: National Cancer Institute of Canada experience. (Submitted)."},{"key":"e_1_2_1_100_2","unstructured":"MacLennanICM.Medical Research Council Annual Review meeting of Leukaemia Trials 1987."},{"key":"e_1_2_1_101_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19860415)57:8 <1685::AID-CNCR2820571310>3.0.CO;2-0"},{"key":"e_1_2_1_102_2","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1200\/JCO.1985.3.5.654","article-title":"Phase II study of recombinant \u03b1\u20102 interferon in resistant multiple myeloma","volume":"5","author":"Costanzi J","year":"1985","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_103_2","first-page":"473","article-title":"Alpha\u20102 interferon\/melphalan\/prednisolone in previously untreated patients with multiple myeloma: A phase I\u2010II trial","volume":"170","author":"Cooper MR","year":"1986","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_104_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1975.95"},{"key":"e_1_2_1_105_2","first-page":"3343","article-title":"Phase I study of 2\u2032deoxycoformycin in acute lymphoblastic leukemia","volume":"41","author":"Poplak DG","year":"1981","journal-title":"Cancer Res"},{"key":"e_1_2_1_106_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(81)91491-4"},{"key":"e_1_2_1_107_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00552725"},{"key":"e_1_2_1_108_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1984.2.12.1336"},{"key":"e_1_2_1_109_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198704023161401"},{"key":"e_1_2_1_110_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5757.325-a"},{"key":"e_1_2_1_111_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-8140(85)80003-7"},{"key":"e_1_2_1_112_2","first-page":"1173","article-title":"Double hemibody irradiation in chemotherapy\u2010resistant multiple myeloma","volume":"68","author":"Thomas PJ","year":"1984","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_113_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1984.tb03989.x"},{"key":"e_1_2_1_114_2","first-page":"181","article-title":"Radiation therapy for paraplegia due to multiple myeloma","volume":"191","author":"Heller P","year":"1965","journal-title":"J Am Med Assoc"},{"key":"e_1_2_1_115_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1978.tb14870.x"},{"key":"e_1_2_1_116_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.6177.1541"},{"key":"e_1_2_1_117_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198406283102607"},{"key":"e_1_2_1_118_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)90191-0"},{"key":"e_1_2_1_119_2","doi-asserted-by":"publisher","DOI":"10.1016\/0221-8747(81)90044-8"},{"key":"e_1_2_1_120_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1985.100"},{"key":"e_1_2_1_121_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198002073020602"},{"key":"e_1_2_1_122_2","first-page":"206","article-title":"Severe renal failure in multiple myeloma","volume":"15","author":"Cosio FC","year":"1981","journal-title":"Clin Nephrol"},{"key":"e_1_2_1_123_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198006053022305"},{"key":"e_1_2_1_124_2","first-page":"151","volume-title":"Clinics in haematology, vol 11. Myeloma and related disorders","author":"Kyle RA.","year":"1982"},{"key":"e_1_2_1_125_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.142.8.1445"},{"key":"e_1_2_1_126_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780290515"},{"key":"e_1_2_1_127_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(86)90715-1"},{"key":"e_1_2_1_128_2","first-page":"221","volume-title":"Clinics in Haematology, vol 11. Myeloma and related disorders","author":"Bergsagel DE.","year":"1979"},{"key":"e_1_2_1_129_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1987.107"},{"key":"e_1_2_1_130_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-105-3-360"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.1987.tb01445.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.1987.tb01445.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T13:37:21Z","timestamp":1711633041000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.1987.tb01445.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1987,11]]},"references-count":129,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1987,11]]}},"alternative-id":["10.1111\/j.1600-0609.1987.tb01445.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.1987.tb01445.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[1987,11]]}}}